Arikayce (amikacin) Liposomal 590 mg Nebuliser Dispersion approved in EU for treatment of nontuberculous mycobacterial lung infections caused by Mycobacterium avium complex in adult non-cystic fibrosis patients with limited treatment options

Pulmovanc liposomal technology enables the delivery of amikacin directly to the lungs, where liposomal amikacin is taken up by infected lung macrophages, while limiting systemic exposure. Arikayce is administered once daily using the Lamira Nebulizer System.

Biospace Inc.